19th Aug 2025 10:48
(Alliance News) - Cambridge Nutritional Sciences PLC on Tuesday announced a swing to an annual profit as costs declined faster than revenue, as it noted it was in a "strong position" to grow through expansion into new markets.
The London-registered medical diagnostics firm offering health and nutrition products said it swung to a pretax profit of GBP1.6 million in the financial year ended March 31, from a loss of GBP745,000 a year prior.
Revenue fell 15% to GBP8.3 million, which the firm noted was below expectations, from GBP9.8 million.
Headcount declined 11% to 84 at the end of the financial year, from 94 a year ago. "This focus on optimising headcount remains important as we develop and move the company forward," the firm said.
Cambridge Nutritional said it has looked to reduced headcounts in key areas "where efficient processes have decreased resourcing requirements whilst also taking the opportunity to review underperforming staff."
It added however that it recognised the need to strengthen its teams which has led to the recruitment of some key roles.
Cost of sales came down 23% to GBP2.9 million from GBP3.7 million, while administrative costs were 11% lower at GBP4.7 million compared to GBP5.3 million.
Looking ahead, Cambridge Nutritional noted that new In Vitro Diagnostic Regulations that will be required for the EU's conformity-assessed CE marking must be adhered to by the end of 2029, when the transition period ends.
Chief Executive Officer James Cooper said: "CNS is in a strong position to grow through expansion into new markets and through greater penetration in existing markets over the coming years. The new sales team members that started in FY25 are filling up the pipeline with opportunities that will be converted through the course of this coming year. Our goal is to sign up a significant number of these over this financial year and begin the process of growing them into long term partners. This will ensure that moving into FY27 we will have a very strong set of clients that will begin to run at full speed, ready to support our growth plans and enable us to continue to invest in the growth of the business."
Chair Carolyn Rand said: "We believe the market has the potential to deliver a high level of growth in the UK and overseas. Gut health and welfare is becoming an increasing area of focus for many different generations of people. There are consistently more and more studies showing the increasing focus and benefits of healthy eating. We believe CNS is well placed to progress from this development and growth and we are therefore very excited about the next few years.
"We aim to be a leading provider of gut health testing and our work on In Vitro Diagnostic Regulations accreditation and gut health education will help to enhance our standing in this exciting area of food testing. The UK market is growing steadily each year, and we have seen a very positive start to the current year. The overseas market is very large, and our sales team have a large number of excited distributors wanting to engage and work with us."
Cambridge Nutritional shares fell 5.7% to 3.30 pence each on Tuesday morning in London.
By Tom Budszus, Alliance News slot editor
Comments and questions to [email protected]
Copyright 2025 Alliance News Ltd. All Rights Reserved.
Related Shares:
Cambr Nutri Sci